Updated:
Ascentage Pharma Group International
Ascentage Pharma: Dajun Yang's biotech firm channels public-market capital into apoptosis-targeting cancer therapies, anchored by a $1.2B Takeda deal.
Ascentage Pharma Group International
Dajun Yang established Ascentage Pharma Group International in 2009, headquartered in Suzhou, China, with a research-and-development hub in the US. The company represents the professionalization of drug-discovery intellectual property, emerging from academic and early-stage research collaboration networks. Rather than family-office wealth, Ascentage's capital base comes from public-market investors and venture backers, structured as a publicly traded biotech operating company. Ascentage develops novel small-molecule drugs that restore programmed cell death — or apoptosis — in cancer cells. Its strategy concentrates on inhibitors targeting Bcl-2, IAP, and MDM2-p53 pathways, alongside a next-generation kinase inhibitor for drug-resistant chronic myeloid leukemia. The pipeline included nine clinical-stage assets as of late 2024, led by the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115). The geographic footprint spans US and Chinese clinical trial sites, with a commercial partnership covering China and select global rights. In June 2024, Ascentage announced a landmark licensing deal with Takeda for olverembatinib — a third-generation BCR-ABL inhibitor — worth up to $1.2 billion in total consideration, signaling the firm's capacity to monetize its pipeline through traditional biotech licensing structures. The firm employs over 500 professionals, with clinical and regulatory operations split between Suzhou and Rockville, Maryland. In addition to its direct drug-development mandate, Ascentage chairs a biotech-focused incubator in the Jiangsu region, linking early-stage research to mid-stage clinical execution — a structure that functions like a venture-studio arm inside a public company. The June 2024 Takeda global license for olverembatinib (per company filings, 2024) marked the largest single-asset out-licensing deal by a China-headquartered biotech at that time, dramatically reshaping the firm's cash runway and validation profile. What separates Ascentage from a conventional biotech is its structural design as a public, asset-financing vehicle rather than a private venture-backed startup. It packages academic apoptosis research into publicly tradable equity, allowing institutional investors to participate in binary clinical-stage risk through liquid markets. Succession design remains early — leadership is still heavily concentrated in the founding scientific team — but the Takeda deal provides the balance-sheet resources to professionalize commercial operations without an emergency capital raise.
General information
Firm type
Asset Manager
Year founded
2009
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Suzhou
Corporate office
Suzhou, Jiangsu, China
Principals
Dajun Yang
Chairman & CEO
Yifan Zhai
Chief Medical Officer
Sector focus
Frequently asked questions
Who runs scientific and investment decisions at Ascentage Pharma?
Dajun Yang, who holds an MD and a PhD in genetics, co-founded the firm and serves as Chairman and CEO, leading both pipeline strategy and capital allocation. Chief Medical Officer Yifan Zhai drives clinical development decisions, including trial design and regulatory submissions in the US and China. The board, which includes venture investors and independent directors, holds ultimate fiduciary authority over licensing deals and public-market offerings.
How is Ascentage Pharma funded, and what does that mean for investors?
Ascentage is a publicly traded company listed on the Hong Kong Stock Exchange under ticker 6855. It raised roughly $410 million through its 2019 IPO and a 2020 follow-on offering, and it supplements public-market capital with out-licensing revenue — most notably a $100 million upfront payment from Takeda in 2024. Institutional investors can purchase common shares through HKEX, gaining direct exposure to binary clinical-trial outcomes rather than investing through a fund vehicle.
What is the Takeda deal, and why does it matter?
In June 2024, Ascentage granted Takeda exclusive global rights — excluding China and a few other Asian markets — to olverembatinib, a third-generation BCR-ABL inhibitor for drug-resistant chronic myeloid leukemia. The deal included a $100 million upfront payment, potential milestone payments pushing the total to $1.2 billion, and double-digit royalties on future sales. It is widely recognized as the largest single-asset out-licensing agreement from a China-based biotech (per company disclosure, 2024).
Which drug candidates are closest to regulatory approval?
The lead asset is lisaftoclax (APG-2575), a Bcl-2 inhibitor in Phase 3 trials for chronic lymphocytic leukemia and small lymphocytic lymphoma — positioning it as a potential competitor to AbbVie's blockbuster drug venetoclax. Olverembatinib, the subject of the Takeda deal, is already approved in China for certain T315I-mutant CML patients and is advancing toward global registration. The firm's pipeline also includes Phase 2-stage assets targeting MDM2-p53 and IAP pathways.
Where does Ascentage maintain physical operations?
The firm is headquartered in Suzhou, China, within the Suzhou Industrial Park, a biotech cluster that houses numerous drug-development startups. Ascentage also operates a significant R&D and clinical development office in Rockville, Maryland, which anchors its US clinical trials and regulatory interactions with the FDA. Manufacturing and chemistry operations are concentrated in China.
Does Ascentage participate in venture-capital or fund structures?
No. Ascentage is an operating biotech company, not a fund. However, its chairman's role in chairing a Jiangsu-based biotech incubator creates an adjacent pipeline-sourcing mechanism that functions similarly to a venture-studio arm — de-risking early-stage assets before they enter Ascentage's own pipeline or partnering orbit.
What is the firm's posture on co-development and global partnerships?
Ascentage actively pursues regional and global partnership structures rather than building its own commercial sales force outside China. The Takeda deal represents the template: retain China and select Asia-Pacific rights while licensing global commercial rights to a major pharma partner in exchange for tiered milestones and royalties. The firm has previously structured similar, smaller partnerships with global players for other pipeline assets (per public record, 2020–2023).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: